Shanghai bokang bioengineering co., LTD Report issue

Government Phase 1

Organization Overview

First Clinical Trial
2018
NCT03554889
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Shanghai bokang bioengineering co., LTD

Active Ingredients

Drugs in Phase 1 Trials (2)

autologous natural killer cells (1 trial)

nimotuzumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2